Manning & Napier Group's AZN Position Overview
Manning & Napier Group (via Manning & Napier Advisors LLC) currently holds 1.76 M shares of AstraZeneca PLC (AZN) worth $135.2 M, representing 1.72% of the portfolio. First purchased in 2013-Q2, this long-term strategic position has been held for 50 quarters.
Based on 13F filings since 2013, Manning & Napier Group has maintained a long-term strategic position in AZN, representing a significant commitment to this investment thesis. Largest addition occurred in Q4 2023, adding 2.05 M shares. Largest reduction occurred in Q2 2025, reducing 902,693 shares.
Analysis based on 13F filings available since 2013 Q2
Manning & Napier Group's AstraZeneca PLC (AZN) Holding Value Over Time
Track share changes against reported price movement
Quarterly AstraZeneca PLC (AZN) Trades by Manning & Napier Group
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2013 | +1.02 M | Add 0.00% | 1.02 M | $23.65 |
| Q3 2013 | -5,444 | Reduce 0.53% | 1.02 M | $25.96 |
| Q4 2013 | -36,134 | Reduce 3.55% | 981,756 | $29.68 |
| Q1 2014 | -62,618 | Reduce 6.38% | 919,138 | $32.44 |
| Q2 2014 | -301,078 | Reduce 32.76% | 618,060 | $37.15 |
| Q3 2014 | +16,300 | Add 2.64% | 634,360 | $35.72 |
| Q4 2014 | -178,620 | Reduce 28.16% | 455,740 | $35.19 |
| Q4 2015 | +4,100 | Add 0.90% | 459,840 | $33.95 |
| Q1 2016 | +27,930 | Add 6.07% | 487,770 | $28.16 |
| Q3 2016 | +8,190 | Add 1.68% | 495,960 | $32.86 |
| Q1 2017 | -495,960 | Sold Out | 495,960 | $0.00 |
| Q2 2023 | +724,965 | New Buy | 724,965 | $71.57 |
| Q3 2023 | +4,183 | Add 0.58% | 729,148 | $67.72 |
| Q4 2023 | +2.05 M | Add 281.16% | 2.78 M | $67.35 |
| Q1 2024 | +31,857 | Add 1.15% | 2.81 M | $67.75 |
| Q2 2024 | +2.42 M | Add 0.00% | 2.42 M | $77.99 |
| Q3 2024 | +764,562 | Add 31.64% | 3.18 M | $77.91 |
| Q4 2024 | +564,297 | Add 17.74% | 3.75 M | $65.52 |
| Q1 2025 | -690,303 | Reduce 18.43% | 3.06 M | $73.50 |
| Q2 2025 | -902,693 | Reduce 29.55% | 2.15 M | $69.88 |
| Q3 2025 | -390,342 | Reduce 18.13% | 1.76 M | $76.72 |
Manning & Napier Group's AstraZeneca PLC Investment FAQs
Manning & Napier Group first purchased AstraZeneca PLC (AZN) in Q2 2013, acquiring 1,023,334 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Manning & Napier Group has held AstraZeneca PLC (AZN) for 50 quarters since Q2 2013. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Manning & Napier Group's largest addition to AstraZeneca PLC (AZN) was in Q2 2024, adding 2,416,672 shares worth $188.48 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Manning & Napier Group's firm, Manning & Napier Advisors LLC, owns 1,762,193 shares of AstraZeneca PLC (AZN), valued at approximately $135.2 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, AstraZeneca PLC (AZN) represents approximately 1.72% of Manning & Napier Group's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Manning & Napier Group's peak holding in AstraZeneca PLC (AZN) was 3,745,531 shares, as reported at the end of Q4 2024. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.